MBAI
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
No Graham Number available; valuation is purely speculative.
- P/B of 2.80 is high for a company with negative ROE
- No P/E or PEG available due to lack of earnings
Growth is measured by loss reduction, not revenue generation.
- EPS is becoming less negative YoY
- No revenue growth data provided
- High cash burn implied by ROA/ROE
Long-term trend is one of significant value destruction.
- Recent 1-year recovery
- 5-year return of -94.0%
- 25 quarters of negative earnings
Critical liquidity risk and poor operational health.
- Low absolute debt
- Piotroski F-Score 3/9 (Weak)
- Current Ratio 0.71 (Below 1.0)
Company is in a capital-preservation/burn phase.
- No dividend history
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MBAI and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MBAI
Check-Cap Ltd.
Primary
|
-94.0% | +34.3% | +175.7% | -5.8% | +4.0% | +5.3% |
|
CUPR
Cuprina Holdings (Cayman) Limited
Peer
|
-85.5% | -85.5% | -85.5% | -45.3% | +62.6% | +105.3% |
|
IVF
INVO Fertility, Inc.
Peer
|
-100.0% | -100.0% | -99.0% | -93.2% | -53.3% | -19.9% |
|
GDTC
CytoMed Therapeutics Limited
Peer
|
-75.0% | -75.0% | -63.5% | -55.6% | -5.7% | +1.2% |
|
BNGO
Bionano Genomics, Inc.
Peer
|
-100.0% | -99.8% | -64.6% | -35.8% | +0.9% | +3.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2024
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MBAI
Check-Cap Ltd.
|
BEARISH | $13.12M | - | -130.1% | -% | $1.8 | |
|
CUPR
Cuprina Holdings (Cayman) Limited
|
BEARISH | $12.9M | - | -139.1% | -% | $0.6 | Compare |
|
IVF
INVO Fertility, Inc.
|
BEARISH | $13.99M | - | -% | -% | $2.01 | Compare |
|
GDTC
CytoMed Therapeutics Limited
|
BEARISH | $11.83M | - | -50.3% | -% | $1.0 | Compare |
|
BNGO
Bionano Genomics, Inc.
|
BEARISH | $11.7M | - | -78.2% | -134.4% | $1.15 | Compare |
Past News Coverage
Recent headlines mentioning MBAI from our newsroom.